Peter H. Howarth

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 214 publications

Mepolizumab improves outcomes in patients with CRSwNP with one or more prior nasal polyp surgeries.

Mepolizumab improves outcomes in patients with CRSwNP with one or more prior nasal polyp surgeries.

Journal: Rhinology
Published: May 28, 2026

Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

Journal: American journal of respiratory and critical care medicine
Published: May 11, 2026

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

Journal: Allergy
Published: March 31, 2026

Reconsidering biologic treatment recommendations for CRSwNP without asthma in EUFOREA guidelines.

Reconsidering biologic treatment recommendations for CRSwNP without asthma in EUFOREA guidelines.

Journal: Rhinology
Published: March 27, 2026

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?

Journal: International forum of allergy & rhinology
Published: March 17, 2026

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.

Journal: The Lancet. Respiratory medicine
Published: March 02, 2026

Depemokimab reduces asthma exacerbations similarly to other biologics: systematic trial review and indirect treatment comparison.

Depemokimab reduces asthma exacerbations similarly to other biologics: systematic trial review and indirect treatment comparison.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: January 26, 2026

Depemokimab reduces asthma exacerbations similarly to other biologics.

Depemokimab reduces asthma exacerbations similarly to other biologics.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: January 26, 2026

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).

Journal: American journal of respiratory and critical care medicine
Published: December 16, 2025

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE).

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE).

Journal: American journal of respiratory and critical care medicine
Published: December 16, 2025

Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis.

Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis.

Journal: Frontiers in allergy
Published: December 12, 2025

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps.

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps.

Journal: Journal of clinical pharmacology
Published: November 25, 2025
Showing 1-12 of 214

Last Updated: 09/26/2026